Back to results
US 11,998,443 B2Granted
Method for stimulating retinal cells and treating vision loss
AssigneeLambdaVision Incorporated
InventorsRobert R Birge, Nicole Wagner, Jordan A Greco
Life of this patent
Estimating the term…
Abstract
Protein-based subretinal implants offer a new approach to restoring vision for patients blinded by conditions such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). The present invention relates to bacteriorhodopsin-based (BR-based) retinal implants that can be implanted in a subretinal position to replace degenerated photoreceptor cells.
Claims46
A method for treating a patient having loss of vision caused by loss of retinal cells, comprising,
- (a) implanting into an eye of the patient a bacteriorhodopsin-based retinal implant, and
- (b) activating the implant with a light source,
- wherein the implant stimulates retinal cells such that the stimulation is provided at a resolution with pixel dimensions less than about 500 μm, or less than about 350 μm, or less than about 250 μm, or less than about 200 μm, or less than about 150 μm, or less than about 100 μm, or less than about 75 μm, or less than about 50 μm, or less than about 40 μm, or less than about 30 μm, or less than about 25 μm.
The method according to 7 wherein the substrate layer is less than 100 μm in thickness and contains an evenly distributed array of apertures of a diameter less than about 100 μm.
A method for treating a patient having loss of vision caused by loss of retinal cells, comprising,
- (a) implanting into an eye of the patient a bacteriorhodopsin-based retinal implant, and
- (b) activating the implant with a light source,
- wherein the implant stimulates retinal cells such that the stimulation is provided at a resolution limited by (i) the diffraction limit of the light source or (ii) when the retinal implant further comprises an ion-permeable substrate, the aperture diameter and density of the ion-permeable substrate.
A method for treating a patient having loss of vision caused by loss of retinal cells, comprising,
- (a) implanting into an eye of the patient a bacteriorhodopsin-based retinal implant, and
- (b) activating the implant with a light source,
- wherein the implant stimulates retinal cells such that the stimulation is provided at a resolution with a pixel density of about 4 pixels/mm2 and pixel dimension of about 500 μm, or with a pixel density of about 8 pixels/mm2 and pixel diameter of about 350 μm, or with a pixel density of about 16 pixels/mm2 and pixel diameter of about 250 μm, or with a pixel density of about 25 pixels/mm2 and pixel diameter of about 200 μm, or with a pixel density of about 44 pixels/mm2 and pixel diameter of about 150 μm, or with a pixel density of about 100 pixels/mm2 and pixel diameter of about 100 μm, or with a pixel density of about 178 pixels/mm2 and pixel diameter of about 75 μm, or with a pixel density of about 400 pixels/mm2 and pixel diameter of about 50 μm, or with a pixel density of about 625 pixels/mm2 and pixel diameter of about 40 μm, or with a pixel density of about 1111 pixels/mm2 and pixel diameter of about 30 μm, or with a pixel density of about 1600 pixels/mm2 and pixel diameter of about 25 μm.
A method for stimulating retinal cells comprising,
- (a) contacting the retinal cells with a bacteriorhodopsin-based retinal implant,
- (b) activating the implant with a light source,
- wherein
- (i) wherein the implant stimulates retinal cells such that the stimulation is provided at a resolution with pixel dimensions less than about 500 μm, or less than about 350 μm, or less than about 250 μm, or less than about 200 μm, or less than about 150 μm, or less than about 100 μm, or less than about 75 μm, or less than about 50 μm, or less than about 40 μm, or less than about 30 μm, or less than about 25 μm;
- or
- (ii) wherein the implant stimulates retinal cells such that the stimulation is provided at a resolution limited by (a) the diffraction limit of the light source or (b) when the retinal implant further comprises an ion-permeable substrate, the aperture diameter and density of the ion-permeable substrate;
- or
- (iii) wherein the implant stimulates retinal cells such that the stimulation is provided at a resolution with a pixel density of about 4 pixels/mm2 and pixel dimension of about 500 μm, or with a pixel density of about 8 pixels/mm2 and pixel diameter of about 350 μm, or with a pixel density of about 16 pixels/mm2 and pixel diameter of about 250 μm, or with a pixel density of about 25 pixels/mm2 and pixel diameter of about 200 μm, or with a pixel density of about 44 pixels/mm2 and pixel diameter of about 150 μm, or with a pixel density of about 100 pixels/mm2 and pixel diameter of about 100 μm, or with a pixel density of about 178 pixels/mm2 and pixel diameter of about 75 μm, or with a pixel density of about 400 pixels/mm2 and pixel diameter of about 50 μm, or with a pixel density of about 625 pixels/mm2 and pixel diameter of about 40 μm, or with a pixel density of about 1111 pixels/mm2 and pixel diameter of about 30 μm, or with a pixel density of about 1600 pixels/mm2 and pixel diameter of about 25 μm.
5 more elements
A retinal implant for treating a patient having loss of vision caused by loss of retinal cells, comprising, (i) a retinal implant that when activated by a light source stimulates retinal cells such that the stimulation is provided at a resolution with pixel dimensions less than about 500 μm, or less than about 350 μm, or less than about 250 μm, or less than about 200 μm, or less than about 150 μm, or less than about 100 μm, or less than about 75 μm, or less than about 50 μm, or less than about 40 μm, or less than about 30 μm, or less than about 25 μm, or
- (ii) a retinal implant for treating a patient having loss of vision caused by loss of retinal cells, comprising, a retinal implant that when activated by a light source stimulates retinal cells such that the stimulation is provided at a resolution limited by (a) the diffraction limit of the light source or (b) when the retinal implant further comprises an ion-permeable substrate, the aperture diameter and density of the ion-permeable substrate, or
- (iii) a retinal implant for treating a patient having loss of vision caused by loss of retinal cells, comprising, a retinal implant that when activated by a light source stimulates retinal cells such that the stimulation is provided at a resolution with a pixel density of about 4 pixels/mm2 and pixel dimension of about 500 μm, or with a pixel density of about 8 pixels/mm2 and pixel diameter of about 350 μm, or with a pixel density of about 16 pixels/mm2 and pixel diameter of about 250 μm, or with a pixel density of about 25 pixels/mm2 and pixel diameter of about 200 μm, or with a pixel density of about 44 pixels/mm2 and pixel diameter of about 150 μm, or with a pixel density of about 100 pixels/mm2 and pixel diameter of about 100 μm, or with a pixel density of about 178 pixels/mm2 and pixel diameter of about 75 μm, or with a pixel density of about 400 pixels/mm2 and pixel diameter of about 50 μm, or with a pixel density of about 625 pixels/mm2 and pixel diameter of about 40 μm, or with a pixel density of about 1111 pixels/mm2 and pixel diameter of about 30 μm, or with a pixel density of about 1600 pixels/mm2 and pixel diameter of about 25 μm,
- wherein the implant is a bacteriorhodopsin-based retinal implant that comprises at least one substrate layer and a bacteriorhodopsin film, wherein the bacteriorhodopsin film comprises a plurality of individual layers of a native bacteriorhodopsin or a bacteriorhodopsin mutant, wherein each individual layer of the native bacteriorhodopsin or bacteriorhodopsin mutant alternates with a layer of a cationic polymer, and wherein the bacteriorhodopsin mutant is selected from the group consisting of a chloride pump mutant, a dipole mutant, a photocycle mutant, a gold-binding mutant, an ion pump mutant, a Q-state mutant, and combinations thereof.
The retinal implant according to 38 wherein the substrate layer is less than 100 μm in thickness and contains an evenly distributed array of apertures of a diameter less than about 100 μm.
A retinal implant for treating a patient having loss of vision caused by loss of retinal cells, comprising,
- a retinal implant that when activated by a light source stimulates retinal cells such that the stimulation is provided at a resolution with pixel dimensions less than about 500 μm, or less than about 350 μm, or less than about 250 μm, or less than about 200 μm, or less than about 150 μm, or less than about 100 μm, or less than about 75 μm, or less than about 50 μm, or less than about 40 μm, or less than about 30 μm, or less than about 25 μm,
- wherein the implant is a bacteriorhodopsin-based retinal implant that comprises at least one substrate layer and a bacteriorhodopsin film, wherein the bacteriorhodopsin film comprises a plurality of individual layers of a native bacteriorhodopsin or a bacteriorhodopsin mutant, wherein each individual layer of the native bacteriorhodopsin or bacteriorhodopsin mutant alternates with a layer of a cationic polymer, and wherein the bacteriorhodopsin mutant is selected from the group consisting of a chloride pump mutant, a dipole mutant, a photocycle mutant, a gold-binding mutant, an ion pump mutant, a Q-state mutant, and combinations thereof.
A retinal implant for treating a patient having loss of vision caused by loss of retinal cells, comprising,
- a retinal implant that when activated by a light source stimulates retinal cells such that the stimulation is provided at a resolution limited by (a) the diffraction limit of the light source or (b) when the retinal implant further comprises an ion-permeable substrate, the aperture diameter and density of the ion-permeable substrate,
- wherein the implant is a bacteriorhodopsin-based retinal implant that comprises at least one substrate layer and a bacteriorhodopsin film, wherein the bacteriorhodopsin film comprises a plurality of individual layers of a native bacteriorhodopsin or a bacteriorhodopsin mutant, wherein each individual layer of the native bacteriorhodopsin or bacteriorhodopsin mutant alternates with a layer of a cationic polymer, and wherein the bacteriorhodopsin mutant is selected from the group consisting of a chloride pump mutant, a dipole mutant, a photocycle mutant, a gold-binding mutant, an ion pump mutant, a Q-state mutant, and combinations thereof.
A retinal implant for treating a patient having loss of vision caused by loss of retinal cells, comprising,
- a retinal implant that when activated by a light source stimulates retinal cells such that the stimulation is provided at a resolution with a pixel density of about 4 pixels/mm2 and pixel dimension of about 500 μm, or with a pixel density of about 8 pixels/mm2 and pixel diameter of about 350 μm, or with a pixel density of about 16 pixels/mm2 and pixel diameter of about 250 μm, or with a pixel density of about 25 pixels/mm2 and pixel diameter of about 200 μm, or with a pixel density of about 44 pixels/mm2 and pixel diameter of about 150 μm, or with a pixel density of about 100 pixels/mm2 and pixel diameter of about 100 μm, or with a pixel density of about 178 pixels/mm2 and pixel diameter of about 75 μm, or with a pixel density of about 400 pixels/mm2 and pixel diameter of about 50 μm, or with a pixel density of about 625 pixels/mm2 and pixel diameter of about 40 μm, or with a pixel density of about 1111 pixels/mm2 and pixel diameter of about 30 μm, or with a pixel density of about 1600 pixels/mm2 and pixel diameter of about 25 μm,
- wherein the implant is a bacteriorhodopsin-based retinal implant that comprises at least one substrate layer and a bacteriorhodopsin film, wherein the bacteriorhodopsin film comprises a plurality of individual layers of a native bacteriorhodopsin or a bacteriorhodopsin mutant, wherein each individual layer of the native bacteriorhodopsin or bacteriorhodopsin mutant alternates with a layer of a cationic polymer, and wherein the bacteriorhodopsin mutant is selected from the group consisting of a chloride pump mutant, a dipole mutant, a photocycle mutant, a gold-binding mutant, an ion pump mutant, a Q-state mutant, and combinations thereof.
Dependencies are inferred from the claim text.